Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and...
13 insider purchases on record · latest filing 2025-09-24.
Insiders have also filed 12 sale transactions at JSPR.